Cathay, Efung Back Anti-ageing Drug Developer
22 Oct 2026
US$ 20.00
Cathay Capital and Efung Capital were party to the series A funding round of Nanjing Reju Therapeutics Co Ltd (Reju...
Related Publications
Subscribers’ Weekly for the week ending 23 Oct 2026...
Listen to Australia/New Zealand News (Subscribers' Weekly 23 Oct 2026)...
Connect With Us
We love to share Asia PE insights and news from time to time. Drop us your email address if you like to hear from us.
Rest assured that your email address will not be shared, as we hate spams as much as you do.